Balyasny Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-32,105
| Closed | -$124K | – | 1982 |
|
|
2018
Q2 | $124K | Buy |
32,105
+10,930
| +52% | +$42.2K | ﹤0.01% | 1515 |
|
|
2018
Q1 | $134K | Buy |
21,175
+2,796
| +15% | +$17.7K | ﹤0.01% | 1618 |
|
|
2017
Q4 | $148K | Buy |
+18,379
| New | +$148K | ﹤0.01% | 1701 |
|
|
2017
Q3 | – | Sell |
-1,627
| Closed | -$16K | – | 1943 |
|
|
2017
Q2 | $16K | Buy |
+1,627
| New | +$16K | ﹤0.01% | 1232 |
|
|
2017
Q1 | – | Sell |
-31,457
| Closed | -$1.01M | – | 1613 |
|
|
2016
Q4 | $1.01M | Sell |
31,457
-92,466
| -75% | -$2.97M | 0.01% | 831 |
|
|
2016
Q3 | $6.19M | Buy |
123,923
+119,708
| +2,840% | +$5.98M | 0.04% | 462 |
|
|
2016
Q2 | $179K | Buy |
+4,215
| New | +$179K | ﹤0.01% | 880 |
|
|
2015
Q3 | – | Sell |
-152,649
| Closed | -$14.9M | – | 1306 |
|
|
2015
Q2 | $14.9M | Buy |
152,649
+24,262
| +19% | +$2.36M | 0.09% | 228 |
|
|
2015
Q1 | $12M | Buy |
+128,387
| New | +$12M | 0.1% | 254 |
|
|
2014
Q3 | – | Sell |
-97,206
| Closed | -$5.58M | – | 702 |
|
|
2014
Q2 | $5.58M | Buy |
97,206
+56,653
| +140% | +$3.25M | 0.06% | 263 |
|
|
2014
Q1 | $1.61M | Sell |
40,553
-96,330
| -70% | -$3.82M | 0.02% | 361 |
|
|
2013
Q4 | $5.74M | Buy |
+136,883
| New | +$5.74M | 0.07% | 244 |
|